摘要
目的探讨采用双歧杆菌四联活菌片联合三联疗法对幽门螺杆菌阳性消化性溃疡进行治疗的临床效果。方法随机选取该院2013年4月—2015年2月期间收治的幽门螺杆菌阳性消化性溃疡患者92例,按照治疗方法的不同将其分为对照组和观察组,其中对照组患者仅使用三联疗法进行治疗,观察组患者在三联疗法的基础上联合双歧杆菌四联活菌片进行治疗,对两组患者的临床治疗效果进行观察分析。结果观察组患者治疗结束时其Hp清除率(89.13%)、生长抑素(90.2±20.1)pg/m L和胃动素水平(357.9±83.2)ng/m L均明显优于对照组患者(54.35%)、(69.4±19.5)pg/m L、(439.3±70.2)ng/m L,差异有统计学意义(P<0.05)。结论采用双歧杆菌四联活菌片联合三联疗法治疗幽门螺杆菌阳性消化道溃疡,效果显著,能够有效改善患者的临床症状,建议在临床上进一步推广。
Objective To explore the clinical effect of Bifidobacterium Tetravaccine Tablets combined with triple therapy on Helicobacter pylori positive peptic ulcer. Methods Ninety-two cases with Helicobacter pylori positive peptic ulcer admitted in our hospital from April 2013 to February 2015 were randomly selected and divided into the control group and the observation group in accordance with the treatment method. Patients in the control group were treated by triple therapy, while those in the observation group were treated by triple therapy combined with Bifidobacterium Tetravaccine Tablets. And the clinical efficacy of the two groups was observed and analyzed. Results At the end of treatment, compared with the control group, the observation group had much higher Hp clearance(89.13% vs 54.35%), obviously higher somatostatin level [(90.2±20.1)pg/m L vs(69.4±19.5)pg/m L], significantly lower motilin level [(357.9±83.2)ng/m L vs(439.3±70.2)ng/m L] with statistically significant difference(P<0.05). Conclusion For patients with Helicobacter pylori positive peptic ulcer, Bifidobacterium Tetravaccine Tablets combined with triple therapy has significant effect, which can effectively improve the clinical symptoms of the patients, so it is recommended to be further promoted in clinical practice.
出处
《中外医疗》
2015年第29期4-6,共3页
China & Foreign Medical Treatment
关键词
幽门螺杆菌
消化性溃疡
三联疗法
双歧杆菌四联活菌片
Helicobacter pylori
Peptic ulcer
Triple therapy
Bifidobacterium Tetravaccine Tablets
